2012-11-20 18:38:15 - New Pharmaceuticals market report from GlobalData: "Hyperparathyroidism - Analysis and Market Forecasts to 2019"
The global hyperparathyroidism therapeutics market is forecast to grow to reach $2.6 billion by 2019. This moderate growth is primarily attributed to the increase in the hyperparathyroidism patient population and the expected launches of two novel drugs: CTAP101 and KAI-4169 IV. The major barriers for the hyperparathyroidism therapeutics market during forecast period are the introduction of bundled dialysis payment system in the US and the expected patent expirations of all three leading branded drugs in the market: Sensipar/Mimpara, Zemplar and Hectorol. The hyperparathyroidism pipeline is weak, with only seven molecules in various stages of development, including four first-in-class molecules and three me-too products. Amgen and Abbott are the leading companies in the current competitive landscape. Amgen is likely to maintain
its position during the forecast period due to its acquisition in July 2012 of KAI Pharmaceuticals and its promising pipeline molecule KAI-4169.
Full Report Details at
- www.fastmr.com/prod/504970_hyperparathyroidism_analysis_and_mark ..
* Overview of hyperparathyroidism, including epidemiology, etiology, symptoms, diagnosis, pathophysiology, management and treatment guidelines.
* Annualized hyperparathyroidism therapeutics market revenue, annual cost of therapy and forecast for eight years to 2019.
* Pipeline analysis: Comprehensive data split across different phases, emerging trends and mechanisms of action under development, including calcium sensing receptor agonist, vitamin D pro-hormone, vitamin D receptor agonist and CYP24 enzyme inhibitor.
* Analysis of the current and future market competition in the global hyperparathyroidism therapeutics market.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
* Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the hyperparathyroidism therapeutics market.
Reasons to buy
* Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
* Develop business strategies by understanding the trends shaping and driving the global hyperparathyroidism therapeutics market.
* Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hyperparathyroidism therapeutics market in future.
* Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
* Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
* Track drug sales in the global hyperparathyroidism therapeutics market from 2011-2019.
* Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Companies Mentioned in this Report: Amgen Inc., Abbott Laboratories, Cytochroma Inc., KAI Pharmaceuticals Inc.
Partial Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.3 Risk Factors
3.2.2 Diagnosed Prevalence
3.4 Diagnosis and Referral
3.5 Treatment Guidelines
3.6 Disease Management
3.6.1 Primary Hyperparathyroidism
3.6.2 Secondary Hyperparathyroidism
3.6.3 Tertiary Hyperparathyroidism
4 Competitive Assessment
4.2 Strategic Competitor Assessment
4.3 Product Profile - Major Brands
4.3.1 Sensipar (cinacalcet)
4.3.2 Zemplar (paricalcitol)
4.3.3 Hectorol (doxercalciferol)
4.3.4 Oxarol (maxacalcitol)
5 Opportunity and Unmet Need
5.2 Lower Adverse Effect on Serum Calcium and Phosphorus Level
5.3 New Treatment Options for Primary Hyperparathyroidism
5.4 Disease Awareness and Screening Programs in Primary Hyperparathyroidism
5.5 Convenient Dosing Regimen
5.6 Guidelines for Tertiary Hyperparathyroidism Management
6 Pipeline Assessment
6.2 Strategic Pipeline Assessment
6.3 Pipeline by Phases of Development
6.3.1 Phase III Pipeline
6.3.2 Phase II Pipeline
6.3.3 Phase I Pipeline
6.3.4 Preclinical Pipeline
6.3.5 Discovery Pipeline
6.4 Pipeline by Mechanism of Action
6.5 Technology Trends Analytic Framework
6.6 Hyperparathyroidism - Promising Drugs in Clinical Development
6.6.2 KAI-4169 IV
7 Clinical Trials Mapping
7.1 Clinical Trials by Country
7.2 Clinical Trials by Phase
7.3 Clinical Trials by Trial Status
7.4 Prominent Sponsors
8 Current and Future Players
8.2 Trends in Corporate Strategy
8.3 Company Profiles
8.3.1 Amgen Inc.
8.3.2 Abbott Laboratories
8.3.3 Cytochroma Inc.
8.3.4 KAI Pharmaceuticals Inc.
8.3.5 Other Companies in the Hyperparathyroidism Therapeutics Market
9 Licensing and Partnership Deals
9.2 Key Deals and Alliances in the Past 12 Months
10 Market Outlook
10.1 Seven Major Markets Overview
10.2 Regional Analysis
Full Table of Contents is available at:
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.